Neuromedin U-25 (human)

Neuromedin U-25 human is the active form of neuromedin U in human. Neuromedin U-25 human inhibits glucose-stimulated insulin secretion, which leads to early-onset obesity. Neuromedin U-25 serves as vasoconstrictor in human vascular beds[1][2].

Product Specifications

CAS Number

[312306-89-1]

UNSPSC

12352209

Target

Endogenous Metabolite

Type

Peptides

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/neuromedin-u-25-human.html

Purity

99.05

Solubility

10 mM in DMSO

Smiles

C([C@@H](NC([C@H](CC1=CC=CC=C1)NC([C@@H](NC([C@H](CC2=CC=CC=C2)NC([C@H](CC3=CC=C(O)C=C3)NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(=O)[C@H]4N(C([C@@H](NC([C@@H](NC([C@H](CC5=CC=CC=C5)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC6=CC=CC=C6)N)=O)CCCNC(=N)N)=O)C(C)C)=O)CC(O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)=O)CCC(N)=O)=O)CO)=O)CCC4)CC7=CC=CC=C7)=O)C)=O)CO)=O)CCC(N)=O)=O)CO)=O)CCCNC(=N)N)=O)=O)=O)=O)CC(C)C)=O)=O)CCCNC(=N)N)(=O)N8[C@H](C(N[C@H](C(N[C@@H](CC(N)=O)C(N)=O)=O)CCCNC(=N)N)=O)CCC8

Molecular Formula

C141H203N41O38

Molecular Weight

3080.37

References & Citations

[1]Mitchell JD, et al., Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system. Cardiovasc Res. 2009 Feb 1;81 (2) :353-61. |[2]Alfa RW, et al., Suppression of insulin production and secretion by a decretin hormone. Cell Metab. 2015 Feb 3;21 (2) :323-334.